News
06-10-2011, 04:10 AM
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.
More... (http://www.news-medical.net/news/20110610/FDA-accepts-ZIOPHARMs-IND-for-ZIN-ATI-001-to-treat-melanoma.aspx)
More... (http://www.news-medical.net/news/20110610/FDA-accepts-ZIOPHARMs-IND-for-ZIN-ATI-001-to-treat-melanoma.aspx)